Loading...
Drug Pricing Investigation: AbbVie - Humira and Imbruvica
House Committee on Oversight and Reform
House Committee on Oversight and Reform
Citations
Altmetric:
Abstract
The House Committee on Oversight and Reform issued a Staff Report on the pricing practices of AbbVie, Inc. concerning the drugs Humira and Imbruvica. The report includes recommendations.
Date
2021-05-18
Document Type
House Staff Report
Serial Number
Document Length
57 pages
Congress
117
Relation
DOI
Keywords
Staff Reports, House
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs
Cited Hearings
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part I)," 116th Cong., H.Hrg. 116-122, (2020, September 30)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part II)," 116th Cong., H.Hrg. 116-123, (2020, October 1)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., H.Hrg. 117-22, (2021, May 18)
• House Committee on Oversight and Reform, hearing on "The Patient Perspective: The Devastating Impacts of Skyrocketing Drug Prices on American Families," 116th Cong., H.Hrg. 116-55, (2019, July 26)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices: Testimony from the CEOs (Part II)," 116th Cong., H.Hrg. 116-123, (2020, October 1)
• House Committee on Oversight and Reform, hearing on "Unsustainable Drug Prices (Part III): Testimony from AbbVie CEO Richard Gonzalez," 117th Cong., H.Hrg. 117-22, (2021, May 18)
• House Committee on Oversight and Reform, hearing on "The Patient Perspective: The Devastating Impacts of Skyrocketing Drug Prices on American Families," 116th Cong., H.Hrg. 116-55, (2019, July 26)